Bogatsa Evangelia, Lazaridis George, Stivanaki Chrysoula, Timotheadou Eleni
Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou Hospital, 56429 Thessaloniki, Greece.
Cancers (Basel). 2024 Apr 23;16(9):1619. doi: 10.3390/cancers16091619.
Non-small cell lung cancer, even when diagnosed in early stages, has been linked with poor survival rates and distant recurrence patterns. Novel therapeutic approaches harnessing the immune system have been implemented in early stages, following the designated steps of advanced NSCLC treatment strategies. Immune-checkpoint inhibitor (ICI) regimens as monotherapy, combinational, or alongside chemotherapy have been intensely investigated as adjuvant, neoadjuvant, and, more recently, perioperative therapeutic strategies, representing pivotal milestones in the evolution of early lung cancer management while holding great potential for the future. The subject of current ongoing research is optimizing treatment outcomes for patient subsets with different needs and identifying biomarkers that could be predictive of response while translating the trials' endpoints to survival rates. The aim of this review is to discuss all current treatment options with the pros and cons of each, persistent challenges, and future perspectives on immunotherapy as illuminating the path to a new era for resectable NSCLC.
非小细胞肺癌即使在早期被诊断，也与生存率低和远处复发模式相关。遵循晚期非小细胞肺癌治疗策略的指定步骤，利用免疫系统的新型治疗方法已在早期实施。免疫检查点抑制剂（ICI）方案作为单一疗法、联合疗法或与化疗联合，已作为辅助、新辅助以及最近的围手术期治疗策略进行了深入研究，这代表了早期肺癌治疗演变中的关键里程碑，同时对未来具有巨大潜力。当前正在进行的研究主题是优化针对不同需求患者亚组的治疗结果，并确定可预测反应的生物标志物，同时将试验终点转化为生存率。本综述的目的是讨论所有当前的治疗选择，包括每种选择的优缺点、持续存在的挑战以及免疫疗法的未来前景，从而为可切除非小细胞肺癌的新时代指明道路。
